FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324150760> ?p ?o ?g. }

• W2324150760 abstract "Background In human TNFα (hTNFα) transgenic mice (TTg), active anti-TNFα immunization with the kinoid of TNFα (TNF-K) induces polyclonal anti-hTNFα antibodies and results in amelioration of arthritis1,2,3Objectives 1) To compare the efficacy of TNF-K to that of infliximab (IFX) and to that of TNF-K and IFX co-administration. 2) To evaluate whether the titers of anti-hTNFα antibodies (Ab) induced by active immunization are a determinant of TNF-K efficacy.Methods Forty-eight TTg mice received one of the following treatments: TNF-K immunization (TNFK group); weekly IFX all along study duration (IFXw0-15); TNF-K plus weekly IFX for 4 weeks (TNF-K+IFX), weekly IFX for 4 weeks (IFXw0-4); PBS. Animals were sacrificed at week 16. Anti-hTNFα Ab titers IFX serum levels and clinical and histological scores were compared.Results All TNF-K immunized mice (TNF-K and TNF-K+IFX) produced anti-hTNFα Ab. Ab titers were higher in the TNF-K group vs. TNF-K+IFX (p<0.001) and inversely correlated to histological inflammation (R=-0.78; p=0.0001) and destruction (R= -0.67; p=0.001). Mice with high vs. low anti-hTNFα Ab titers had less histological inflammation and destruction (p<0.05). Similarly, the serum levels of infliximab in IFX-only treated mice showed inverse correlation with histological inflammation (R= - 0.56; p<0.05) and destruction scores (R -0.57; p<0.05). TNF-K and long-term IFX treatment (IFXw0-15) didn’t differ in clinical and histological amelioration of arthritis. The group that received TNF-K and IFX co-administration (TNF-K+IFX) had a more rapid clinical improvement (p<0.05) but higher histological inflammation and destruction (p<0.05) compared to the group that received solely TNF-K.Conclusions In a model of TNFα–dependent arthritis, protection from articular damage by TNF-K correlates with the titers anti-hTNFα Ab induced by active anti-hTNFα immunization. TNF-K and IFX have similar efficacy. The co-administration of TNF-K and a short course of IFX does not result in less articular damage vs. solely TNF-K, probably due to lower anti-hTNFα Ab production. These results are relevant for future development of active anti-TNFα immunization in RA.1. Le Buanec H, Delavallee L, Bessis N, et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 2006;103:19442-7.2. Delavallee L, Le Buanec H, Bessis N, et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008;67:1332-8.3. Delavallee L, Semerano L, Assier E, et al. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009;11:R195.Disclosure of Interest L. Semerano: None Declared, J. Biton: None Declared, L. Delavallee: None Declared, E. Duvallet: None Declared, E. Assier: None Declared, N. Bessis: None Declared, E. Bernier Employee of: Neovacs S.A., O. Dhellin Employee of: Neovacs S.A., G. Grouard-Vogel Employee of: Neovacs S.A., M.-C. Boissier Grant/Research support from: Neovacs S.A., Consultant for: Neovacs S.A." @default.
• W2324150760 created "2016-06-24" @default.
• W2324150760 creator A5002499536 @default.
• W2324150760 creator A5003843873 @default.
• W2324150760 creator A5004067733 @default.
• W2324150760 creator A5033170183 @default.
• W2324150760 creator A5034504880 @default.
• W2324150760 creator A5040332746 @default.
• W2324150760 creator A5043160192 @default.
• W2324150760 creator A5057462252 @default.
• W2324150760 creator A5060166514 @default.
• W2324150760 creator A5075990267 @default.
• W2324150760 date "2013-06-01" @default.
• W2324150760 modified "2023-10-01" @default.
• W2324150760 title "AB0172 Protection from articular damage by passive or active anti-TNF alpha immunotherapy in human-TNF alpha transgenic mice depends on anti-TNF alpha antibody levels" @default.
• W2324150760 doi "https://doi.org/10.1136/annrheumdis-2012-eular.172" @default.
• W2324150760 hasPublicationYear "2013" @default.
• W2324150760 type Work @default.
• W2324150760 sameAs 2324150760 @default.
• W2324150760 citedByCount "0" @default.
• W2324150760 crossrefType "journal-article" @default.
• W2324150760 hasAuthorship W2324150760A5002499536 @default.
• W2324150760 hasAuthorship W2324150760A5003843873 @default.
• W2324150760 hasAuthorship W2324150760A5004067733 @default.
• W2324150760 hasAuthorship W2324150760A5033170183 @default.
• W2324150760 hasAuthorship W2324150760A5034504880 @default.
• W2324150760 hasAuthorship W2324150760A5040332746 @default.
• W2324150760 hasAuthorship W2324150760A5043160192 @default.
• W2324150760 hasAuthorship W2324150760A5057462252 @default.
• W2324150760 hasAuthorship W2324150760A5060166514 @default.
• W2324150760 hasAuthorship W2324150760A5075990267 @default.
• W2324150760 hasConcept C126322002 @default.
• W2324150760 hasConcept C159654299 @default.
• W2324150760 hasConcept C17991360 @default.
• W2324150760 hasConcept C203014093 @default.
• W2324150760 hasConcept C2776914184 @default.
• W2324150760 hasConcept C2777138892 @default.
• W2324150760 hasConcept C2780132546 @default.
• W2324150760 hasConcept C32611913 @default.
• W2324150760 hasConcept C71924100 @default.
• W2324150760 hasConceptScore W2324150760C126322002 @default.
• W2324150760 hasConceptScore W2324150760C159654299 @default.
• W2324150760 hasConceptScore W2324150760C17991360 @default.
• W2324150760 hasConceptScore W2324150760C203014093 @default.
• W2324150760 hasConceptScore W2324150760C2776914184 @default.
• W2324150760 hasConceptScore W2324150760C2777138892 @default.
• W2324150760 hasConceptScore W2324150760C2780132546 @default.
• W2324150760 hasConceptScore W2324150760C32611913 @default.
• W2324150760 hasConceptScore W2324150760C71924100 @default.
• W2324150760 hasLocation W23241507601 @default.
• W2324150760 hasOpenAccess W2324150760 @default.
• W2324150760 hasPrimaryLocation W23241507601 @default.
• W2324150760 hasRelatedWork W1965176337 @default.
• W2324150760 hasRelatedWork W1970919452 @default.
• W2324150760 hasRelatedWork W1990237417 @default.
• W2324150760 hasRelatedWork W2028658282 @default.
• W2324150760 hasRelatedWork W2033484883 @default.
• W2324150760 hasRelatedWork W2078261443 @default.
• W2324150760 hasRelatedWork W2079066573 @default.
• W2324150760 hasRelatedWork W2143274626 @default.
• W2324150760 hasRelatedWork W2215460969 @default.
• W2324150760 hasRelatedWork W2319316010 @default.
• W2324150760 hasRelatedWork W2329965131 @default.
• W2324150760 hasRelatedWork W2330113523 @default.
• W2324150760 hasRelatedWork W2371030627 @default.
• W2324150760 hasRelatedWork W2385971868 @default.
• W2324150760 hasRelatedWork W2419289756 @default.
• W2324150760 hasRelatedWork W250039085 @default.
• W2324150760 hasRelatedWork W2580540891 @default.
• W2324150760 hasRelatedWork W2947459817 @default.
• W2324150760 hasRelatedWork W2955471408 @default.
• W2324150760 hasRelatedWork W3141036743 @default.
• W2324150760 isParatext "false" @default.
• W2324150760 isRetracted "false" @default.
• W2324150760 magId "2324150760" @default.
• W2324150760 workType "article" @default.